Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Chemokine Therapeutics Announces 2006 Financial and Operating Results
May 1st, 2007
Chemokine Therapeutics Corp. (the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced highlights and the financial and operating results of the year ended December 31, 2006. 2006 Highlights: Commencement and continued enrollment of subjects to the Phase Ib/II clinical study of CTCE-9908 to assess the safety and preliminary signs of efficacy of CTCE-9908 after repeated administration in late stage cancer patients. Collaborations with several prestigious academic institutions to study the benefits of CTCE-9908 in...
Source: Cancer Weekly (2007-05-01)
|
